Noveome Biotherapeutics is a Pittsburgh-based clinical-stage biopharmaceutical company developing ST266, a non-cellular biologic derived from the secretome of cultured amnion-derived epithelial cells. Its scalable GMP process produces the investigational biologic for research and clinical development across challenging diseases and conditions, with the company describing activity in clinical and preclinical studies.
Cook MyoSite, IncCook MyoSite, Inc., a Cook Group subsidiary established in 2002, develops muscle-derived cell therapies and manufactures human muscle cell products for research and clinical development. Based in Pittsburgh, the company also provides contract manufacturing and research services grounded in more than two decades of muscle-cell technology experience.PITTSBURGH, PA
Generian PharmaceuticalsFormed by UPMC Enterprises, Generian Pharmaceuticals is a Boston- and Pittsburgh-based preclinical biotechnology company developing orally available small-molecule therapeutics for difficult-to-drug diseases often dominated by biologics. Its discovery platform screens proteins in their native cellular environment, then combines target-binding data with disease-relevant phenotypic testing to advance candidates that modulate protein activity, stability, or degradation. The company’s research includes proprietary programs and a collaboration with Astellas for novel targets.
Elevai Skincare, IncPittsburgh-based Elevai Skincare, Inc. is a biotech skincare company developing exosome-based products for professional treatments and at-home care. Its Cell Zero Exosomes™ are derived from ethically sourced human umbilical cord stem cells, with formulations built on more than 15 years of stem cell and exosome research and over 1,000 clinical studies. Elevai’s system is used by more than 300 clinics and includes facial skincare as well as a scalp serum for fuller-looking hair.PITTSBURGH, PA
Krystal Biotech, IncPittsburgh-based Krystal Biotech develops and commercializes redosable genetic medicines for rare diseases, using an engineered HSV-1 vector platform designed for focal, minimally invasive gene delivery. Its first commercial product, VYJUVEK®, is the first and only redosable gene therapy for dystrophic epidermolysis bullosa, while two U.S. GMP facilities—including a roughly 155,000-square-foot ASTRA site—support manufacturing and pipeline development. Krystal is fully integrated across vector design, gene therapy manufacturing and commercialization.325412PITTSBURGH, PA